دورية أكاديمية
أعرض في EDS

Pan-cancer analysis predict that FAT1 is a therapeutic target and immunotherapy biomarker for multiple cancer types including non-small cell lung cancer.

التفاصيل البيبلوغرافية
العنوان: Pan-cancer analysis predict that FAT1 is a therapeutic target and immunotherapy biomarker for multiple cancer types including non-small cell lung cancer.
المؤلفون: Ding C; Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, China., Huang H; Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, China., Wu D; Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, China., Chen C; Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, China., Hua Y; Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, China., Liu J; Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, China., Li Y; Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, China., Liu H; Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, China., Chen J; Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, China.; Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, China.
المصدر: Frontiers in immunology [Front Immunol] 2024 May 24; Vol. 15, pp. 1369073. Date of Electronic Publication: 2024 May 24 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Lausanne : Frontiers Research Foundation]
مواضيع طبية MeSH: Biomarkers, Tumor* , Carcinoma, Non-Small-Cell Lung*/immunology , Carcinoma, Non-Small-Cell Lung*/therapy , Lung Neoplasms*/immunology , Lung Neoplasms*/therapy , Lung Neoplasms*/genetics , Immunotherapy*/methods, Humans ; Animals ; Mice ; Cadherins/metabolism ; Cadherins/genetics ; Cell Line, Tumor ; Prognosis ; Gene Expression Regulation, Neoplastic ; Cell Proliferation ; Cell Movement ; Computational Biology/methods
مستخلص: FAT1, a substantial transmembrane protein, plays a pivotal role in cellular adhesion and cell signaling. Numerous studies have documented frequent alterations in FAT1 across various cancer types, with its aberrant expression being linked to unfavorable survival rates and tumor progression. In the present investigation, we employed bioinformatic analyses, as well as in vitro and in vivo experiments to elucidate the functional significance of FAT1 in pan-cancer, with a primary focus on lung cancer. Our findings unveiled FAT1 overexpression in diverse cancer types, including lung cancer, concomitant with its association with an unfavorable prognosis. Furthermore, FAT1 is intricately involved in immune-related pathways and demonstrates a strong correlation with the expression of immune checkpoint genes. The suppression of FAT1 in lung cancer cells results in reduced cell proliferation, migration, and invasion. These collective findings suggest that FAT1 has potential utility both as a biomarker and as a therapeutic target for lung cancer.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2024 Ding, Huang, Wu, Chen, Hua, Liu, Li, Liu and Chen.)
References: J Exp Clin Cancer Res. 2022 Aug 15;41(1):248. (PMID: 35965328)
Nature. 2021 Jan;589(7842):448-455. (PMID: 33328637)
Cancer Lett. 2017 Jul 1;397:83-93. (PMID: 28366557)
Nature. 2016 Nov 24;539(7630):575-578. (PMID: 27828948)
Clin Chest Med. 2020 Mar;41(1):1-24. (PMID: 32008623)
Cancer Discov. 2012 May;2(5):401-4. (PMID: 22588877)
Annu Rev Pathol. 2011;6:49-69. (PMID: 20887192)
Nat Rev Gastroenterol Hepatol. 2019 Feb;16(2):121-136. (PMID: 30451972)
Nat Commun. 2019 Apr 3;10(1):1523. (PMID: 30944313)
Hum Cell. 2021 Jul;34(4):1215-1226. (PMID: 33890248)
Front Cardiovasc Med. 2022 May 11;9:905717. (PMID: 35647082)
J Hematol Oncol. 2021 Jan 7;14(1):10. (PMID: 33413496)
Cell Rep. 2020 Jan 21;30(3):793-806.e6. (PMID: 31968254)
Cancer Control. 2022 Jan-Dec;29:10732748221076682. (PMID: 35212236)
Front Immunol. 2020 May 07;11:784. (PMID: 32457745)
Nat Rev Drug Discov. 2014 Jan;13(1):63-79. (PMID: 24336504)
Oncol Lett. 2021 May;21(5):398. (PMID: 33777221)
Science. 1997 Mar 21;275(5307):1787-90. (PMID: 9065402)
Adv Drug Deliv Rev. 2022 Aug;187:114365. (PMID: 35667465)
Int J Cancer. 2018 Feb 15;142(4):805-812. (PMID: 28994107)
Neoplasia. 2017 Aug;19(8):649-658. (PMID: 28732212)
Sci Rep. 2021 Jan 8;11(1):40. (PMID: 33420124)
J Cell Biol. 2006 May 8;173(3):417-29. (PMID: 16682528)
J Natl Cancer Inst. 2015 Nov 17;108(1):. (PMID: 26577528)
Cancer Sci. 2023 Jan;114(1):63-74. (PMID: 35524544)
J Cell Sci. 2008 Jan 15;121(Pt 2):226-33. (PMID: 18187454)
Nucleic Acids Res. 2021 Jan 8;49(D1):D605-D612. (PMID: 33237311)
Genome Med. 2020 Feb 26;12(1):21. (PMID: 32102694)
Mol Cancer. 2021 Oct 11;20(1):131. (PMID: 34635121)
Genomics. 1995 Nov 20;30(2):207-23. (PMID: 8586420)
J Gynecol Oncol. 2017 Nov;28(6):e83. (PMID: 29027401)
Med Res Rev. 2014 Jan;34(1):190-221. (PMID: 23720094)
Epigenetics. 2013 Feb;8(2):149-56. (PMID: 23291739)
Int J Cancer. 2019 Dec 1;145(11):3140-3151. (PMID: 31020993)
Front Immunol. 2022 May 26;13:813888. (PMID: 35720420)
Cancers (Basel). 2021 Mar 19;13(6):. (PMID: 33808631)
Cell. 2017 Jun 1;169(6):985-999. (PMID: 28575679)
NPJ Precis Oncol. 2022 Jun 23;6(1):46. (PMID: 35739249)
فهرسة مساهمة: Keywords: FAT1; bioinformatics; immune; pan-cancer; prognosis
المشرفين على المادة: 0 (Biomarkers, Tumor)
0 (FAT1 protein, human)
0 (Cadherins)
تواريخ الأحداث: Date Created: 20240610 Date Completed: 20240610 Latest Revision: 20240611
رمز التحديث: 20240611
مُعرف محوري في PubMed: PMC11157030
DOI: 10.3389/fimmu.2024.1369073
PMID: 38855103
قاعدة البيانات: MEDLINE
الوصف
تدمد:1664-3224
DOI:10.3389/fimmu.2024.1369073